Cidara Therapeutics Inc (NASDAQ:CDTX) Acquisition by Merck & Co Inc

RBC Capital sets a price target of $221.50 for NASDAQ:CDTX, aligning with Merck & Co Inc's acquisition offer.Merck's acquisition of Cidara represents a significant $9.2 billion cash deal, more than doubling Cidara's stock price pre-announcement.The current price of CDTX is $217.71, marking a 105.41% increase, with a trading volume of 17.29 million shares.Cidara Therapeutics Inc (NASDAQ:CDTX) is a biotechnology company focused on developing innovative therapies to treat serious diseases. Recently, RBC Capita ...